Nova Mentis Life Science Corp.

05/29/2023

Last month, we begun recruiting participants into the first-ever clinical trial investigating the safety and efficacy of psilocybin for Fragile X syndrome.

Why do we think psilocybin can help with this condition? Learn more in our latest blog.

04/28/2023

Our latest e-newsletter is hot off the press!

It’s your source for news and information about our research & drug development program.

Your direct source for news and information about our research and drug development program.

04/21/2023

Restartlifeco

04/07/2023

Restarlifeco

02/28/2023

Our February e-newsletter is out!

Check out the latest news and information about Nova’s research & drug development program.

Your direct source for news and information about our research and drug development program.

02/22/2023

'KGK and its client Nova Mentis NMLSF are set to conduct this pioneering clinical trial to study the effects of take-home microdose psilocybin on the cognitive and behavioral symptoms associated with FXS.'

via Benzinga | KGK Science

Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and added to the list of measures calling for some sort of psychedelics legalization, while s...

02/20/2023

“We believe that this study will be an impactful assessment of the potential of psilocybin in a disorder that truly affects the lives of many families.”

The Canadian government has cleared KGK Science's Phase 2a trial testing NM-1001, a psilocybin microdose therapy, in fragile X syndrome.

02/15/2023

"We are eager to begin recruiting participants as we seek to better understand the therapeutic potential of psilocybin in the treatment of fragile X syndrome."

KGK Science will begin with its partner Nova Mentis Life Science a clinical trial assessing psilocybin as a therapy for fragile X syndrome.

01/31/2023

Check out our latest e-newsletter!

It’s your source for news and information about our research & drug development program.

Your direct source for news and information about our research and drug development program.

01/30/2023

Autism is the fastest growing developmental disability in the world and many families are struggling to find therapeutic solutions that actually work.

Why do we believe psilocybin has the potential to be an important treatment option for autism?

Read more about the therapeutic potential of psilocybin and Nova’s upcoming Health Canada approved clinical study in our latest blog!

Our solution is to unlock the science of synthetic psilocybin using a classic drug development approach. And, validate behavioural testing with

01/24/2023

“Growing up with my brother was unlike anything else. While other children had siblings to play and joke around with, I had a brother who seemed like he lived in another world entirely.”

Derek Ivany, Nova’s new Executive Chairman, shares his personal story of why his quest to help his autistic brother led him on a journey to support new research into alternative treatment options.

Growing up with my brother was unlike anything else. While other children had siblings to play and joke around with, I had a brother who seemed like he lived in another world entirely.I never really understood why he always stared at the ceiling or preferred to wear winter jackets in…

12/30/2022

“We are eager to gather the necessary clinical data to develop a groundbreaking new therapy to help improve the behavioral and cognitive symptoms associated with autism." - Nova Mentis

| The Dales Report | KGK Science

Psilocybin therapy for Fragile X Syndrome, the major genetic cause of Autism Spectrum Disorder, has received approval from Health Canada i